Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity
Michael Huss,1 Praveen Duhan,2 Preetam Gandhi,3 Chien-Wei Chen,4 Carsten Spannhuth,3 Vinod Kumar5 1Child and Adolescent Psychiatry, University Medicine, Mainz, Germany; 2Global Medical Affairs, Novartis Healthcare Pvt. Ltd., Hyderabad, India; 3Development Franchise, Established Medicine Neuroscienc...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-07-01
|
Series: | Neuropsychiatric Disease and Treatment |
Subjects: | |
Online Access: | https://www.dovepress.com/methylphenidate-dose-optimization-for-adhd-treatment-review-of-safety--peer-reviewed-article-NDT |
id |
doaj-c6b9b283f2d5497aa7c00386ee560f18 |
---|---|
record_format |
Article |
spelling |
doaj-c6b9b283f2d5497aa7c00386ee560f182020-11-24T22:20:55ZengDove Medical PressNeuropsychiatric Disease and Treatment1178-20212017-07-01Volume 131741175133576Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessityHuss MDuhan PGandhi PChen CWSpannhuth CWKumar VMichael Huss,1 Praveen Duhan,2 Preetam Gandhi,3 Chien-Wei Chen,4 Carsten Spannhuth,3 Vinod Kumar5 1Child and Adolescent Psychiatry, University Medicine, Mainz, Germany; 2Global Medical Affairs, Novartis Healthcare Pvt. Ltd., Hyderabad, India; 3Development Franchise, Established Medicine Neuroscience, Novartis Pharma AG, Basel, Switzerland; 4Biostatistics Cardio-Metabolic & Established Medicine, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 5Established Medicines, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Abstract: Attention-deficit/hyperactivity disorder (ADHD) is a chronic psychiatric disorder characterized by hyperactivity and/or inattention and is often associated with a substantial impact on psychosocial functioning. Methylphenidate (MPH), a central nervous system stimulant, is commonly used for pharmacological treatment of adults and children with ADHD. Current practice guidelines recommend optimizing MPH dosage to individual patient needs; however, the clinical benefits of individual dose optimization compared with fixed-dose regimens remain unclear. Here we review the available literature on MPH dose optimization from clinical trials and real-world experience on ADHD management. In addition, we report safety and efficacy data from the largest MPH modified-release long-acting Phase III clinical trial conducted to examine benefits of dose optimization in adults with ADHD. Overall, MPH is an effective ADHD treatment with a good safety profile; data suggest that dose optimization may enhance the safety and efficacy of treatment. Further research is required to establish the extent to which short-term clinical benefits of MPH dose optimization translate into improved long-term outcomes for patients with ADHD. Keywords: methylphenidate, dose optimization, attention-deficit/hyperactivity disorder, ADHDhttps://www.dovepress.com/methylphenidate-dose-optimization-for-adhd-treatment-review-of-safety--peer-reviewed-article-NDTMethylphenidateDose optimizationAttention-deficit/hyperactivity disorderADHD |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Huss M Duhan P Gandhi P Chen CW Spannhuth CW Kumar V |
spellingShingle |
Huss M Duhan P Gandhi P Chen CW Spannhuth CW Kumar V Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity Neuropsychiatric Disease and Treatment Methylphenidate Dose optimization Attention-deficit/hyperactivity disorder ADHD |
author_facet |
Huss M Duhan P Gandhi P Chen CW Spannhuth CW Kumar V |
author_sort |
Huss M |
title |
Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity |
title_short |
Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity |
title_full |
Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity |
title_fullStr |
Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity |
title_full_unstemmed |
Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity |
title_sort |
methylphenidate dose optimization for adhd treatment: review of safety, efficacy, and clinical necessity |
publisher |
Dove Medical Press |
series |
Neuropsychiatric Disease and Treatment |
issn |
1178-2021 |
publishDate |
2017-07-01 |
description |
Michael Huss,1 Praveen Duhan,2 Preetam Gandhi,3 Chien-Wei Chen,4 Carsten Spannhuth,3 Vinod Kumar5 1Child and Adolescent Psychiatry, University Medicine, Mainz, Germany; 2Global Medical Affairs, Novartis Healthcare Pvt. Ltd., Hyderabad, India; 3Development Franchise, Established Medicine Neuroscience, Novartis Pharma AG, Basel, Switzerland; 4Biostatistics Cardio-Metabolic & Established Medicine, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 5Established Medicines, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Abstract: Attention-deficit/hyperactivity disorder (ADHD) is a chronic psychiatric disorder characterized by hyperactivity and/or inattention and is often associated with a substantial impact on psychosocial functioning. Methylphenidate (MPH), a central nervous system stimulant, is commonly used for pharmacological treatment of adults and children with ADHD. Current practice guidelines recommend optimizing MPH dosage to individual patient needs; however, the clinical benefits of individual dose optimization compared with fixed-dose regimens remain unclear. Here we review the available literature on MPH dose optimization from clinical trials and real-world experience on ADHD management. In addition, we report safety and efficacy data from the largest MPH modified-release long-acting Phase III clinical trial conducted to examine benefits of dose optimization in adults with ADHD. Overall, MPH is an effective ADHD treatment with a good safety profile; data suggest that dose optimization may enhance the safety and efficacy of treatment. Further research is required to establish the extent to which short-term clinical benefits of MPH dose optimization translate into improved long-term outcomes for patients with ADHD. Keywords: methylphenidate, dose optimization, attention-deficit/hyperactivity disorder, ADHD |
topic |
Methylphenidate Dose optimization Attention-deficit/hyperactivity disorder ADHD |
url |
https://www.dovepress.com/methylphenidate-dose-optimization-for-adhd-treatment-review-of-safety--peer-reviewed-article-NDT |
work_keys_str_mv |
AT hussm methylphenidatedoseoptimizationforadhdtreatmentreviewofsafetyefficacyandclinicalnecessity AT duhanp methylphenidatedoseoptimizationforadhdtreatmentreviewofsafetyefficacyandclinicalnecessity AT gandhip methylphenidatedoseoptimizationforadhdtreatmentreviewofsafetyefficacyandclinicalnecessity AT chencw methylphenidatedoseoptimizationforadhdtreatmentreviewofsafetyefficacyandclinicalnecessity AT spannhuthcw methylphenidatedoseoptimizationforadhdtreatmentreviewofsafetyefficacyandclinicalnecessity AT kumarv methylphenidatedoseoptimizationforadhdtreatmentreviewofsafetyefficacyandclinicalnecessity |
_version_ |
1725773178711572480 |